Here’s something that’ll surprise you: Canada is about to become the first major Western country where you can get generic Ozempic.
Not in five years. Not after the US or Europe. Starting January 2026.
And honestly? It happened because of what might be the most expensive paperwork mistake in pharmaceutical history.
How we accidentally got ahead of everyone else
Back in 2019, Novo Nordisk (the company that makes Ozempic) had to pay a maintenance fee of about $450 to keep their Canadian patent active.
They didn’t pay it.
The patent expired in 2020, even though it was supposed to last until 2026. And here’s the kicker—Canada is the second-largest market for diabetes drugs like this globally.
The only thing keeping generics out since then has been something called “regulatory data exclusivity”—basically, Health Canada gave Novo Nordisk exclusive rights to their clinical trial data. That protection ends January 4, 2026.
What this means for drug plan costs
When generics hit the market, prices typically drop 60-70% compared to the original drug. For context, Ozempic currently costs between $200-$300 per month without insurance, with some online services charging around $320.65 for a monthly supply. Generic versions could bring that down to $60-120 per month.
Companies like Sandoz are already lined up to launch generic semaglutide in Canada as soon as the regulatory window opens. More competition means even better pricing.
How your drug plan will likely change
Most Canadian drug plans do not cover this drug as it is classified as an ‘obesity medication’ or ‘weight management medication’. Canadian insurers have a special authorization process where the patient must be diagnosed with Type 2 diabetes. The reality is that there are many people trying to avoid Type 2 diabetes, and because they don’t have the official diagnosis, they can’t get coverage.
This change in price may have some employers/plans that currently restrict Ozempic coverage, open it up to include these medications.
Why employers might actually want this on their drug plan now
This is where things get interesting… at $300+ per month, most employers avoided covering semaglutide for weight management—it was just too expensive to justify. But at $60-120 per month? The conversation completely changes.
The business case is getting stronger:
Reduced healthcare costs long-term. Employees with better weight management typically have lower rates of diabetes, heart disease, and joint problems. That means fewer sick days, lower disability claims, and reduced pressure on your health spending account.
Employee retention and attraction. Weight management support is becoming a sought-after benefit, especially among younger workers. Offering coverage for an effective treatment could be a differentiator in competitive hiring markets.
Wellness program ROI. Many employers spend thousands on gym memberships, wellness apps, and weight loss programs with mixed results. For some employees, medically-supervised weight management might be more cost-effective per person.
Productivity benefits. Employees dealing with obesity-related health issues often struggle with energy levels and attendance. Better health outcomes generally translate to better workplace performance.
Preventive care angle. It’s often cheaper to help someone maintain a healthy weight than to treat the complications of diabetes, cardiovascular disease, or mobility issues later.
The math is changing: At current prices, covering weight management might cost your plan $3,600 per employee per year. With generics, that drops to potentially $1,400 per employee per year—suddenly much more manageable for targeted coverage.
The diabetes vs. weight loss coverage question
Right now, most drug plans cover Ozempic for Type 2 diabetes but not for weight loss. The generic versions will likely follow the same coverage rules initially.
But here’s where it gets interesting: when the cost drops from potentially $3,800+ a year to around $1,400 a year, some employers might start considering weight loss coverage as part of their wellness strategy. Lower drug costs make previously unaffordable coverage options suddenly viable.
Timeline and what to watch for
January 2026: Regulatory exclusivity ends Spring 2026: First generics likely hit pharmacy shelves (pending Health Canada approval) By mid-2026: Multiple generic competitors probably in market, driving prices down further
Questions employers should be asking now
Review your current coverage: How many employees are using Ozempic? What’s it costing your plan? This number will improve when the generics come out, but will you considering adding it to your plan for the non-diabetic demographic?
Plan design considerations: When generics arrive, you can amend your plan and add this classification of drugs, but also customize the limit. With more affordable pricing you can consider a $500 or $1,000 per year drug cap to limit exposure.
Communication strategy: How will you explain this addition to your plan? Your advisor is here to help with positioning and brainstorming.
Wellness strategy alignment: Does expanded semaglutide coverage fit with your broader employee health and wellness goals? Do you currently offer a wellness account?
The Bottom Line
This is one of those rare situations where regulatory timing works in our favour. Most countries will be dealing with high-cost Ozempic for years to come. Canada gets affordable generics first.
For drug plan budgeting, this could be significant. Semaglutide drugs have been driving up plan costs across the country. Generic competition should provide real relief for those current claims (the type 2 diabetes patients).
The strategic opportunity: Some forward-thinking employers are already asking about adding weight management coverage to their benefits package once generics arrive. It’s not right for every company, as it will result in higher drug claims. But for organizations focused on comprehensive wellness support, the economics are about to make a lot more sense in supporting this demographic of employees.
At Healthwise Benefits, we’re tracking this closely for our clients and will help navigate any plan changes when the time comes. This kind of market shift doesn’t happen often, and being prepared makes all the difference.
The bottom line? That $450 maintenance fee Novo Nordisk didn’t pay might end up saving Canadian employers millions in drug costs while opening up new possibilities for employee wellness programs. Sometimes the best deals come from the most unexpected places.
Sources:
